Syros Pharmaceuticals (SYRS) Competitors $0.0011 0.00 (-50.00%) As of 03:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SYRS vs. VINC, NCNA, NAVB, SMFL, VRPX, SCPS, ARDS, EVLO, CMRA, and GNCAQShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Vincerx Pharma (VINC), NuCana (NCNA), Navidea Biopharmaceuticals (NAVB), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Its Competitors Vincerx Pharma NuCana Navidea Biopharmaceuticals Smart for Life Virpax Pharmaceuticals Scopus BioPharma Aridis Pharmaceuticals Evelo Biosciences Comera Life Sciences Genocea Biosciences Vincerx Pharma (NASDAQ:VINC) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations. Which has better valuation & earnings, VINC or SYRS? Vincerx Pharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Vincerx Pharma is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVincerx PharmaN/AN/A-$40.16M-$20.600.00Syros Pharmaceuticals$386K0.08-$164.57M-$3.030.00 Do analysts recommend VINC or SYRS? Vincerx Pharma presently has a consensus target price of $40.00, indicating a potential upside of 109,489.04%. Syros Pharmaceuticals has a consensus target price of $1.00, indicating a potential upside of 90,809.09%. Given Vincerx Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Vincerx Pharma is more favorable than Syros Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in VINC or SYRS? 44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor VINC or SYRS? In the previous week, Vincerx Pharma and Vincerx Pharma both had 1 articles in the media. Vincerx Pharma's average media sentiment score of 1.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Overall Sentiment Vincerx Pharma Positive Syros Pharmaceuticals Positive Is VINC or SYRS more profitable? Vincerx Pharma's return on equity of -248.33% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vincerx PharmaN/A -248.33% -132.73% Syros Pharmaceuticals N/A -3,369.56%-97.04% Which has more risk and volatility, VINC or SYRS? Vincerx Pharma has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. SummaryVincerx Pharma beats Syros Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.65M$840.76M$5.79B$10.19BDividend YieldN/A4.84%5.73%4.61%P/E Ratio0.001.1256.1422.50Price / Sales0.0826.51538.28122.35Price / CashN/A19.5625.8129.91Price / Book0.006.6613.256.28Net Income-$164.57M-$4.13M$3.29B$270.38M7 Day PerformanceN/A2.15%0.47%2.70%1 Month PerformanceN/A8.15%4.60%5.99%1 Year PerformanceN/A26.42%73.42%25.94% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.2786 of 5 stars$0.00-50.0%$1.00+90,809.1%-99.9%$1.65M$386K0.00120Short Interest ↓Gap DownVINCVincerx Pharma3.3022 of 5 stars$0.04+38.2%$40.00+88,986.9%-99.7%$235KN/A0.0060Negative NewsShort Interest ↓Gap UpNCNANuCana1.5658 of 5 stars$2.89+0.7%N/A-99.2%$90KN/A0.0030Positive NewsGap UpNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010SMFLSmart for LifeN/A$0.00+17.6%N/A-100.0%$28K$11.11M0.00110Gap UpVRPXVirpax Pharmaceuticals0.1723 of 5 stars$0.01-9.8%N/AN/A$14KN/A0.007Gap DownSCPSScopus BioPharmaN/A$0.00-25.0%N/AN/A$13KN/A0.009Gap DownARDSAridis PharmaceuticalsN/A$0.00-60.0%N/AN/A$11KN/A0.0030Gap DownHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070 Related Companies and Tools Related Companies VINC Alternatives NCNA Alternatives NAVB Alternatives SMFL Alternatives VRPX Alternatives SCPS Alternatives ARDS Alternatives EVLO Alternatives CMRA Alternatives GNCAQ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYRS) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRS Stock Alerts